Cargando...
Scaling Approaches for Pediatric Dose Selection: The Fremanezumab (AJOVY(®)) Journey to Select a Phase 3 Dose Using Pharmacokinetic Data from a Phase 1 Study
Fremanezumab, a fully humanized IgG2Δa/kappa monoclonal antibody, selectively targets the calcitonin-gene-related peptide (CGRP) and prevents it from binding to the CGRP receptor. The safety, tolerability, pharmacokinetics (PK), and efficacy of fremanezumab for treating migraines administered as a o...
Gardado en:
| Publicado en: | Pharmaceutics |
|---|---|
| Main Authors: | , , , |
| Formato: | Artigo |
| Idioma: | Inglês |
| Publicado: |
MDPI
2021
|
| Assuntos: | |
| Acceso en liña: | https://ncbi.nlm.nih.gov/pmc/articles/PMC8225049/ https://ncbi.nlm.nih.gov/pubmed/34074002 https://ncbi.nlm.nih.govhttp://dx.doi.org/10.3390/pharmaceutics13060785 |
| Tags: |
Engadir etiqueta
Sen Etiquetas, Sexa o primeiro en etiquetar este rexistro!
|